Drug
Crizanlizumab clinical trials
Also written SEG101.
Keep track of what changes. Save the crizanlizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 4
Novartis Pharmaceuticals (8) · Washington University School of Medicine (1) · Johns Hopkins University (1) · Reprixys Pharmaceutical Corporation (1) · Children's Hospital Los Angeles (1) · Sheba Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses crizanlizumab is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)RecruitingPhase 3Novartis PharmaceuticalsNCT06439082Written as Crizanlizumab
- Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab StudyRecruitingPhase 4Novartis PharmaceuticalsNCT04657822Written as Crizanlizumab
- Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain MetastasesRecruitingPhase 2Sheba Medical CenterNCT05909618Written as Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO]
- Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell AnemiaNot yet recruitingPhase 1/2Children's Hospital Los AngelesNCT05469828Written as Crizanlizumab
- Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease PatientsActive, not recruitingPhase 3Novartis PharmaceuticalsNCT03814746Written as Crizanlizumab (SEG101)
- Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)CompletedPhase 2Washington University School of MedicineNCT04611880Written as Crizanlizumab
- A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related PriapismCompletedPhase 2Novartis PharmaceuticalsNCT03938454Written as Crizanlizumab
- Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease PatientsCompletedPhase 2Novartis PharmaceuticalsNCT03474965Written as Crizanlizumab
- An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease PatientsCompletedPhase 4Novartis PharmaceuticalsNCT04662931Written as crizanlizumab
- Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)CompletedPhase 2Novartis PharmaceuticalsNCT03264989Written as crizanlizumab
- Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell DiseaseCompletedPhase 2Novartis PharmaceuticalsNCT04053764Written as Crizanlizuamb
- Crizanlizumab for Treating COVID-19 VasculopathyCompletedPhase 2Johns Hopkins UniversityNCT04435184Written as Crizanlizumab
- Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain CrisesCompletedPhase 2Reprixys Pharmaceutical CorporationNCT01895361Written as SelG1
Given in every arm · 1 — crizanlizumab is usual care beside what is tested
As the comparator · 1 — what is tested is compared with crizanlizumab
Codes
What other systems call crizanlizumab · ClinicalTrials.gg INT000604
- MeSH (NLM) C000614139crizanlizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) L7451S9126CRIZANLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2262279One source FDA
- Wikidata Q28209568crizanlizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C133543CrizanlizumabOne source FDA
- DrugBank DB15271One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000614139 | crizanlizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | L7451S9126 | CRIZANLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2262279 | — | One source FDA |
| Wikidata | Q28209568 | crizanlizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C133543 | Crizanlizumab | One source FDA |
| DrugBank | DB15271 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.